Candel Therapeutics Inc $CADL

Recent News (5)

• Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · 01 Sep 2026 NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immun…
• Candel Therapeutics to Present at September Investor Conferences GlobeNewswire · 26 Aug 2026 NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immuno…
• Freedom Broker raises Candel Therapeutics stock price target on trial progress Investing.com · 17 Aug 2026 Freedom Broker raises Candel Therapeutics stock price target on trial progress
• Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 GlobeNewswire · 03 Aug 2026 NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immuno…
• Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston GlobeNewswire · 29 Jul 2026 NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immuno…